Navigation Links
Cumberland Pharmaceuticals Appoints Lee Product Director
Date:1/13/2009

NASHVILLE, Tenn., Jan. 13 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. is pleased to announce the appointment of Barry Lee as Product Director. In this role, Mr. Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for the company.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090113/CLTU094 )

"We are extremely pleased to welcome Mr. Lee to Cumberland's management team," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "As we work to continue to grow the company, we believe Barry's extensive experience and solid track record of success will be extremely valuable in helping Cumberland deliver promising new products to patients who can benefit."

Mr. Lee joins Cumberland from Bayer Healthcare Pharmaceuticals where he held a variety of sales and marketing positions during his 24-year tenure. In addition to leading sales training and development efforts, he oversaw the launch of the company's Yasmin(R) product, which was one of the most successful industry launches of its time, reaching $92 million in net sales its first year on the market. Under his leadership, the product grew to $320 million in net sales over a four-year period. Mr. Lee is a graduate of Texas A & M University.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets branded, prescription products for targeted physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Cumberland Pharmaceuticals web site at www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
2. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
3. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
4. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
5. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
6. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
7. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
8. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
9. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
10. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
11. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... solutions for the detection of foodborne pathogens, today announced ... Sidoti & Company Emerging Growth Conference on September 2 ... the New York Marriott Marquis. A ... the investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... KONG , Aug. 26, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Limited ("MO2"), an entity wholly owned by Mr. Yuen ... Company, has acquired the outstanding shares (the "Shares") of  ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... energy could be a central alternative to petroleum-based energy ... the same energy yield and is more expensive to ... solar energy production on the environment is incomplete, experts ... benefits and detriments of solar power, a research team ...
... Mass.With the potential to save tens of thousands of ... by MassBiologics at the University of Massachusetts and the ... with positive results from a Phase 1 study. The ... (RAB-1) resulted in protective antibody levels in the serum ...
... 16 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: ... Annual Meeting of Shareholders (the "Annual Meeting") held on ... Meeting, shareholders elected John H. Bauer and Phillip M. ... Directors until the Company,s 2013 Annual Meeting. Shareholders approved ...
Cached Biology Technology:Research team assesses environmental impact of organic solar cells 2New treatment for rabies advances after successful phase 1 trial in India 2New treatment for rabies advances after successful phase 1 trial in India 3Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders 2
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... TAMPA, Fla. Dec. 18, 2012 Four ... been named charter fellows to the National Academy ... chair of the Bioengineering Department; Nai Yuen Chen, ... research professor in the Materials Science and Engineering ...
... Neurodegenerative Diseases (DZNE) and the University of Bonn are ... composed of several proteins and plays a key role ... sensor that triggers a chain reaction when activated. As ... foster inflammation are released. This process can be triggered ...
... decorating mantles to the new outfits in display windows calling ... holiday season. For bioenergy researchers, however, fiber composition matters more ... of more than two dozen coils of cellulose, a target ... edition of Nature , an international consortium of researchers ...
Cached Biology News:National Academy of Inventors names four UT Arlington professors as charter fellows 2Alzheimer's disease: Cutting off immune response promises new approach to therapy 2Unraveling the threads: Simplest cotton genome offers clues for fiber improvements 2Unraveling the threads: Simplest cotton genome offers clues for fiber improvements 3
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... powerful application for DNA and protein ... Expression makes complex computational analyses of ... the very latest computing technology to ... sequences are analysed. Features include: Sequence ...
... TYPE II Reacts with most of ... cell keratin of 86 and 58kD and ... keratin reactivity is found on human epidermal ... Immunogen: Human epidermal cells ...
Biology Products: